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Abstrakt 
V posledních letech dochází k významnému nárustu výskytu obezity a s tím 
souvisejícímu nárůstu počtu pacientů s diabetem 2 typu, kardiologickými problémy a 
k předčasnému úmrtí. Mezi nejnebezpečnější formy obezity řadíme její monogenní typ, neboť 
se jedná o nemoc způsobenou kauzální mutaci jediného genu s typickým fenotypem hyperfagie 
a morbidní obezity. Cílem této bakalářské práce je shrnutí nejvýznamnějších genových mutací, 
které mohou způsobovat monogenní formu obezity. První kapitoly nastiňují obecné genetické 
příčiny obezity a význam Leptin-Melanocortinové dráhy s ohledem na její úlohu v energetické 
homeostázi. Navazující kapitoly se věnují genům, které s monogenní obezitou souvisejí, a to 
zejména MC4R, LEP, LEPR, SIM1 a BDNF. Dále je rovněž pojednáváno o nových možnostech 
léčby včetně nového léku setmelanotidu. 
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Abstract 
In recent years the prevalence of obesity has significantly increased, pursued by 
multiplication of patients with type 2 diabetes, cardiological problems and premature death. 
Between the most dangerous forms of obesity belongs its monogenic type as it is a disease 
caused by single causal mutation with typical phenotype of severe obesity and hyperphagia. 
The aspiration of this thesis is to summarise the most important genes, mutation of which may 
cause monogenic type of obesity. The first chapters outline general genetic causes of obesity 
and importance of Leptin-melanocortin pathway in terms of its role in energy homeostasis. 
Subsequent sections identify genes involved in monogenic obesity, e.g. MC4R, LEP, LEPR, 
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Obesity may be one of the most concerning and fastest growing problems of the 21st 
century. World Health Organisation (WHO) characterises obesity as an abnormal or excessive 
fat accumulation that presents a risk to health (WHO | Obesity b.r.). But behind these simple 
words is a multifaceted problem without simple solution. As a disease, obesity touches almost 
every function of the body, while negatively impacting daily life of those suffering from it. 
From higher risks of cardiovascular diseases, cancer and diabetes to frail mental health.  
The difference between sexes in obesity is a well-known fact. The prevalence of obesity 
is usually higher in women than in men in all age groups, steadily increasing from 20 years of 
age and culminating by the age of 50 to 65. The escalated predominance of obesity in 
developing countries is credited to accelerated changes in socioeconomic status, changes in 
demographic and transition to mainly sedentary life style and high-energy diet.  By 2015 nearly 
39 % of world population were estimated to be overweight or obese (Chooi, Ding, and Magkos 
2019); predictions conducted by few studies show even more horrifying estimations, that 
approximately 42 % of the world’s population will be affected by obesity and 11 % by severe 
obesity. Although aim of this particular forecast were adults, childhood obesity have massive 
influence on in, given the stability of surplus fat mass from childhood into adulthood. 
(Finkelstein et al. 2012).  
Obesity is complex illness, originating from broad spectrum of inheritable and 
environmental factors. The advances in molecular genetics and bioinformatics contributed to 
better understanding of molecular and genetical basis of obesity in the last twenty years. 
The impact of genetics, life style and environment on different types of obesity varies 
and estimations differ in studies depending on group of patients and phenotype. The occurrence 
of monogenic types of obesity is a clear proof for genetic impact on obesity, even if the 
prevalence of patients with monogenic obesity across the globe is so far low. 
Gene identification helps to clarify etiology of obesity and its metabolic consequences, 
because if it is possible to identify groups or individuals at risk from their genetical profile, it 







1.  Genetic causes of obesity 





1.1. Syndromic obesity 
Syndromic obesity is an obesity often tied with defined set of phenotypes in addition 
to the early-onset obesity. The cause may be a single gene change or mutation to more extensive 
chromosomal region and to this day over 100 gene forms have been identified. There are certain 
difficulties in determining the etiology of this type of obesity as they are exceedingly rare and 
have complicated mechanism of inheritance influenced by epigenetics or coordination of genes 
(Thaker 2017). There is unfortunately no cure or effective drug treatment for syndromic obesity 
as diet and general management still prove to be most effective (Huvenne et al. 2016). Among 
the most notable syndromes connected to this type of obesity are Prader-Willi syndrome and 
Bardet-Biedl Syndrome which will be briefly described as an example. 
Prader-Willi syndrome (PWS) is model example of syndromic obesity and with 
prevalence estimated to 1:22 000 live births is also regarded as the most common cause. 
Syndrome is caused by the loss of the gene function in an exact region of chromosome 15. Most 
cases of PWS are not inherited, and genetic changes occur randomly during the formation of 
reproductive cells (eggs and sperm) or in early embryonic development. Affected people 
typically have no history of the disorder in their family. Phenotype of this disorder includes 
neonatal hypotonia, behavioural anomalies and often eating disorders with several stages, 
ranging from failure to thrive in infancy to hyperphagia often leading to obesity and type 2 
diabetes. People with PWS have high ghrelin levels, which seems to directly contribute to the 
increased appetite hyperphagia, and obesity (see chapter 2 - Leptin-Melanocortin pathway). 
Bardet-Biedl syndrome (BBS) is a rare disorder with autosomal recessive inheritance. 
Estimated incidence is 1:150 000 live births, with higher prevalence in isolated populations in 
Newfoundland and other small regions. Bardet-Biedl syndrome belongs to a group of 
ciliopathies that are defined by genetic heterogeneity as multitude of different genes were 
identified as a cause: BBS1, BBS2, ARL6 (BBS3), BBS4, BBS5, MKKS (BBS6), BBS7, TTC8 
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(BBS8), BBS9, BBS10, TRIM32 (BBS11), BBS12, MKS1 (BBS13), CEP290 (BBS14), WDPCP 
(BBS15), SDCCAG8 (BBS16), LZTFL1 (BBS17), BBIP1 (BBS18) and IFT27 (BBS19). 
Phenotype slowly progresses from first decade of life and may include limb abnormalities, 
gradual night blindness, loss of colour vision and most importantly, even though birth weight 
may be regular, obesity (Thaker 2017). 
 
 
1.2. Polygenic obesity 
Polygenic obesity, such as we see it in most developed countries is not only affected by 
environment but also by genetic influences.  
Unfortunately, the genetical basis of this type of obesity, even if it is the most common 
cause of obesity, is not known yet. The explanation may be the exceedingly heterogenic group 
of patients which it affects. This may extremely complicate the explanation of the genetic 
nature. As a cause is so far regarded cumulative effect of many genes enforced by obesogenic 
environment. The relationships between these genes, "polygenes" or "polygenic chromosomal 
loci", are very complicated. Their effects can be additive, nonadditive or even contradictory. If 
a genes or polygenes of an individual are studied separately, their contribution to weight gain 
and obesity development is very small, few hundred grams or less. Recent years have brought 
many findings, how the obesity development is also impacted by epigenetic mechanisms such 
as histone modifications, DNA methylation and others. Many chemicals have been identified 
as obesogens or agents that act as endocrine disruptors. All these reasons explain why molecular 
genetic diagnosis is not yet possible in the most common polygenic obesity (Hinney, Vogel, 










1.3. Monogenic obesity 
Monogenic obesity is an illness caused mainly by single gene mutation, mostly tied 
with leptin-melanocortin pathway disrupting signals of hunger and satiety. This bachelor thesis 
is dedicated to this particular problem that seriously affect life of those suffering from it. Classic 
mendelian inheritance have been described for this illness as manifestation often requires 2 
copies of flawed gene in homozygous form. For successful molecular genetic diagnosis the 
screening is mainly performed on very young children, where the effects of environment or 
feeding habits are minor. In current stage of knowledge only 5 % to 7,5 % of the most obese 
children (BMI higher than 97,5 percentiles in the population of the same age) are successfully 

















                            
Figure 1 – percentile BMI graph of the juvenile population. Typical cases of carriers with different mutations are 
shown. Curves of 2 homozygous leptin receptor deficiencies (LepR1 and LepR2) 1 homozygous MC4R deficiency 




It is also crucial not to forget that, although this sub-chapter is about monogenic obesity 
(mutation in one distinct gene), environment and other genes also play a large part in monogenic 
obesity. This is the reason for distinct differences in phenotypes, degree of obesity and its onset 
with the same mutations. 
To this day, more than 30 genes are known, where mutation may clinically be interpreted 
as monogenic obesity, although many of them were discovered as single cases. 
The term “monogenic obesity” has been accepted by the professional community almost 
two decades ago and is commonly used in medical literature but surprisingly though the term 
itself is not yet used in disease classification systems. 
Orphanet (portal for rare diseases and orphan drugs) labels monogenic obesity under 
ORPHA code: 98267 Genetic non-syndromic obesity. In WHO International Classification of 
Diseases, monogenic obesity is not yet classified (ICD-11 - Mortality and Morbidity Statistics 
b.r.). 
Most frequently found mutations in genes are involved in neuronal differentiation of the 
paraventricular nucleus and leptin-melanocortin pathway. The focus of this bachelor thesis is 
on the most common causes of monogenic obesity i.e.  mutations in MC4R, MC3R, LEP, LEPR, 

















2. Leptin-Melanocortin pathway 
Gathered evidence has shown, that central nervous system plays large-scale part in 
safeguarding against obesity and in its development (Jeong, Kim, and Lee 2014). Leptin-
Melanocortin pathway is one of the major aspects in regulation of energy homeostasis and also 
is a major intersection for signals from peripheral organs and overall dietary condition; every 
deviation can possibly have severe physiological impact. So, it stands to reason that each and 
every one of the components must be rigorously controlled and coordinated to achieve 
equilibrium. 
 
2.1. Hypothalamic nuclei – anatomical description 
This controlling effort is centred in diencephalon. Lateral Hypothalamic nucleus with 
peri-fornical area is suggested to have role in positive energy balance, on the other hand the 
paraventricular (PVN), dorsomedial (DMN) and paramedian (PMN) nuclei are involved in 
negative energy balance. Signalling between these two groups of neurons is unified by Arcuate 
nucleus of the hypothalamus. Arcuate nucleus is handily located on the base of the third 
ventricle in area without blood brain barrier (Hypothalamic Nuclei b.r.).
 
Figure 2- Schematic drawing of the hypothalamic pathways involved in regulation of feeding. Solid lines, pathways promoting 




2.2. Arcuate nucleus 
The arcuate nucleus of the hypothalamus is a collection of neurons in the mediobasal 
hypothalamus, adjacent to the third ventricle and the median eminence. Two groups of neurons 
are important from an obesiotological point of view. (i) Proopiomelanocortin (POMC)/ cocaine 
and amphetamine-regulated transcript (CART) neurons and (ii) co-expressing Agouti-related 
peptide (AgRP) /neuropeptide Y (NPY) neurons. Both populations will be discussed in depth 
in next chapters (Minor, Chang, and de Cabo 2009). 
 
2.3. The role of the leptin-melanocortin pathway in the control of food 
intake 
First mentioned neuronal population, POMC is a polypeptide hormone precursor, which 
provides biologically active peptides such as adrenocorticotropin (ACTH) and then alfa 
melanocyte-stimulating hormone (-MSH) by series of enzymatic steps. α-MSH produced by 
neurons in the ventromedial nucleus have important roles in aforementioned regulation of the 
appetite (Yang and Tao 2017). POMC functions as a satiety signalling molecule and uses 
mainly Melanocortin 4-receptor (MC4R) and Melanocortin 3-receptor (MC3R) to inhibit 
hunger. Both MC3R and MC4R are important part of the path and will be further described. 
MC3R is a 7-transmembrane G-protein coupled melanocortin receptor mainly 
expressed in brain and placenta. For the purpose of this work only brain MC3R will be 
characterised. Even though MC3R is a one of the more important portions of the pathway, some 
studies have shown no linkage in mutation in this gene and morbid obesity (Jeong, Kim, and 
Lee 2014).  
Another important 7-transmembrane G-protein coupled melanocortin receptor MC4R is 
restricted almost only to the brain and is greatly involved in achieving and preserving energy 
balance by mediating leptin melanocortin pathway. If mutated, this receptor is strongly tied to 
the increased adiposity and obesity (Qi et al. 2008). 
Second neuronal population of arcuate nucleus produces neuropeptide AgRP and NYP. 
Both work as a neurotransmitter antagonist to POMC and suppress function of MC3R and 
MC4R and work as an antagonist to α-MSH. They subsequently act as a hunger signal, sensing 
hunger hormones or lack thereof, like presence of ghrelin, hormonal product of stomach. 
AgRP/NPY specifically expresses ghrelin receptors to detect aforementioned gut hormone. 
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Ghrelin is not the only hormone which activates AgRP/NPY since low levels of leptin or insulin 
may also work as an excitants. 
From a time perspective we can divide pathway-important signals into two groups, 
(i) acute and (ii) long term. The signals of the first group are released based on momentary 
metabolic needs such as feeling of hunger, appetite, fullness or satiety. To this group may 
belong cholecystokinin (CCK), ghrelin, and peptide YY for their short-term effects (Garfield 
et al. 2009). Signals for the second, long term, group are Leptin and Insulin or signals generally 
tied with adiposity, and as such represents comprehensive metabolic state of the organism 
(Garfield et al. 2009). 
Leptin is protein hormone produced by adipocytes and its amount circulating in the 
blood is proportional to the amount of white adipose tissue. It has vast share in body weight 
regulation. This peptide functions in brain as anorexigenic signal and as a sort of a messenger. 
Leptin brings information about nourishment levels by binding to Leptin receptors (LEPR) 
expressed on various locations around the brain, most notably in the POMC and AgRP/NPY 
neurons, various studies has shown that weakened leptin receptor signalling, lower POMC gene 
expression, therefore it is possible to say that leptin is functioning as a regulator for those 
neurons (Bertile and Raclot 2006). 
Over the years considerable progress has been accomplished mainly in understanding 
of how the adipose tissue engage in energetic homeostasis. White adipose tissue was long 
mistakenly observed as passive storing organ. Only in last two decades is adipose tissue being 
taken as metabolically active unit. Secreting many types of adipokines, including leptin, 
adiponectin and resistin, all of which possess many crucial physiological functions (Sarmento-
Cabral et al. 2017). 
As to how the pathway is functioning, it is necessary to start with desired hormone such 
as leptin, insulin or ghrelin, for this example, leptin will be used. Leptin is released from 
adipocyte and migrates to the brain where it crosses blood-brain barrier by unidirectional 
system (Banks, DiPalma, and Farrell 1999) and then binds to the leptin receptor located on the 
POMC neurons. POMC system then subsequently stimulate signal of satiety by producing and 
releasing -MSH from its axons terminal parts. -MSH than activates MC3R and MC4R which 
leads to decreased eating and larger energy consumption. At the same time leptin also silences 






Figure 3 - stylized scheme of regulation of energy homeostasis by the hypothalamus. ARC, arcuate nucleus; PVN, 
paraventricular nucleus; VMH, ventromedial hypothalamus; LHA, lateral hypothalamic area; AgRP, agouti- related peptide; 
NPY, neuropeptide Y; CART, cocaine-amphetamine-related transcript; POMC, proopiomelanocortin; CLIP, corticotropin- 
like-intermediate lobe peptide, α -MSH, alpha-melatonin stimulating hormone; BDNF, brain-derived neurotrophic factor; 
MCH, melanin concentrating hormone; CRH, corticotropin releasing hormone; DMV, dorsal motor nucleus of the vagus; LC, 













3. Leptin and Leptin receptor 
Out of many genetic disorders connected to the obesity, none have been studied more 
than Ob/Ob and Db/Db mice. In 1994 using positive cloning method a molecular defect was 
determined in obese (Ob) gene (Zhang et al. 1994). Later on, leptin receptor was discovered in 
similar manner in Db/Db mice. 
LEP gene was located on 6th chromosome on mice and in human its location was found 
on 7q31.3. Ob gene was shown to encode 4.5 kilobase long mRNA transcript with a highly 
conserved 167 amino-acid open reading frame. Upon its isolation the encoding protein was 
named leptin from Greek leptos meaning thin. 
As mentioned in previous chapters leptin is found mainly in white adipose tissue, 
however it can also be found in various tissues such as brown adipose tissue, gastric epithelium, 
placenta, skeletal muscle and stomach, albeit amount of leptin found is considerably lower 
(Sobhani 2000). 
Numerous drugs and hormones were described to have effect on leptin regulation, be it by 
protein expression or mRNA. Among them glucocorticoids ( Vos et al. 1995), insulin (Tsai et 
al. 2012) and thyroid hormone triiodothyronine were reported as a mRNA up-regulators and 
3-adrenergic agonist and thiazolidinediones as a down-regulators. Effect of sex hormones was 
also studied and validated. In this study oestrogens were proved to have positive effect on leptin 
expression and androgens negative (Machinal et al. 1999). There are also several physiological 
conditions such as exposure to cold or starvation which can affect level of leptin in plasma. 
Obese patients possess raised levels of leptin in serum and abundance of leptin’s mRNA 
in adipocytes. As a result of hyperleptinemia, most people with multifactorial obesity are 
considered resistant to leptin. Higher level of leptin in serum fails to decrease feeding urges and 
body weight levels as it would in normal situation (Considine et al. 1996). Many mechanisms 
were proposed in terms of how does leptin resistance work. Some studies talk about alternations 
in the crossing the blood brain barrier by leptin or disruptions in developmental programming. 
The genome-wide association has shown a link with polymorphism near the leptin gene with 
obesity in general. This confirms just how important leptin really is in the development of 





Leptin works mainly through activation of cytokine receptor, namely leptin receptor 
(LEPR) which was identified through cloning technique. It is a member of class I cytokine 
receptors family, which consist, among others of growth hormone, prolactin or granulocyte-
colony stimulating factor. There are 5 known isoforms of LEPR, each product of alternative 
RNA splicing of Db (diabetes) gene and it’s possible to sort them into three categories, short, 
long, and soluble. Long Ob-Rb, short Ob-Ra,Ob-Rc, Ob-Rd and soluble Ob-Rf (Tartaglia et al. 
1995).  
Structurally all of those contain the same extracellular domain with 820 AA length and 
transmembrane domain of 34 amino acids (AA); intercellular domain length varies form 303 
AA in long form to 32 AA in short variants. Apart from the exact same extracellular and 
transmembrane domain, OB-R isoforms consist of the same sequence intracellular 29 AA 
which includes constant box 1 motif and JAK tyrosine kinase. Box 2 motif is only present in 
long isoform of OB-R, as it ensures maximal activation of OB-Rb. Short forms of Leptin 
receptor can bind JAK but are not capable of STAT signalling.  
LEPR is present in various tissues, with the biggest presence in hypothalamus nuclei 
such as ARC, DMH and VMH. mRNa of Ob-Rb is highly noticeable especially in ARC as it is 
found in both NPY/AgRP and POMC neurons.  
As is common with cytokine receptors, LEPR does not possess inherent enzymatic 
activity. Instead it uses signalling by Janus kinase (JAK), tyrosine kinase from JAK family. 
Binding of leptin to its receptor cause change of conformation and activate receptor-related 
Janus kinase, ensuring autophosphorylation of JAK1 and JAK2 and tyrosine phosphorylation 
of cytoplasmic domain and downstream transcription factors named STATs. Those molecules 
are greatly expressed in hypothalamus and other brain regions controlling food intake 
(Håkansson and Meister 1998). 
Mutations in leptin gene as well as in Leptin receptor are recognised as a cause of serious 
early-onset hyperphagic childhood obesity with swift weight increase in first few months of 
their lives. Mutations in LEPR gene are as rare as mutations in LEP gene.  And since those 
mutations have autosomal recessive inheritance, most of the described patients are found in 
countries with high prevalence of consanguineous marriages. They are affected by either the 





3.1. Monogenic forms of obesity in leptin gene and Leptin receptor gene 
The first patients with mutation in leptin gene have been described in 1997. For leptin 
deficiency to manifest, both parental alleles must be affected. So far only few dozen families 
with homozygous mutations have been described and most often they hail from countries like 
Pakistan or Turkey (higher chance of consanguinity, as stated before) (Saeed et al. 2012). 
Classic phenotype includes early onset severe obesity identified with hyperphagia, 
hypogonadism and increased frequency of infections. 
LEP gene mutation can be successfully treated by administrating recombinantly 
produced injection of leptin once a day. With this medication, hyperphagia recedes and all the 
other symptoms, obesity included, disappear. Unfortunately, the treatment must continue 
throughout patients whole life, as without those injections they revert to state before treatment. 
Regrettably this therapy does not work for LEPR gene mutations, but recently new drug called 
“Setmelanotide” has been approved and there is hope that it will work for patients with LEPR 
mutations, (see chapter 9 - future treatment).  
Leptin mutations are reported very sparsely but the most prevalent consist of recessive 
frame shift mutation in exon 3 in Ob gene, tagged as G133_VfsX14 (398del) which disrupts 
reading frame and results in 14 abnormal AA and followed by STOP codon. Consequential 
level of leptin in serum is undetectable or very low.    
Another mutation associated with Leptin deficiency is I35del (104_106delTCA). It is 
a homozygous mutation affecting 3 base pair deletion located on exon 2 in Ob gene and as with 
the case before leptin level were below detection (Saeed et al. 2012). 
Most of the LEPR mutations have common symptoms of aberrant eating behaviours, 
selective deposition of fat mass and in adult patients hypogonadotropic hypogonadism 
(Farooqi, Wangensteen, et al. 2007). 
Among the known mutations of LEPR belong frameshift mutation tagged 
p.C186AfsX27 (c.556delT), this mutation causes premature stop codon and thus aberrant 
receptor. Another mutation marked as c.2396-1G>T, is an essential splice site mutation, 
resulting in flawed splicing of Ob transcript by skipping exon 15 and thus encoding shorter and 





4. POMC (proopiomenalocortin) 
The existence of precursor for molecules such as melanotropins (MSHs), adrenotropin 
(ACTH) and -endorphin was confirmed in 1979 by cloning of bovine cDNA. Three POMC 
exons interlaid with extensive introns were identified in bovine and later also in human genome. 
The third exon was discovered to contain sequence of previously known active peptides 
(Slominski 1996). POMC gene is mainly expressed in pituitary, arcuate nucleus of 
hypothalamus and few peripheral tissues like pancreas, placenta and skin. This gene produces 
single protein which migrates to Golgi bodies and is then directed by signal peptide sequence 
into secretory granule where is  processed in cell type specific way to generate different 
neuropeptides (Bateman, Solomon, and Bennett 1990).  Between the most important 
neuropeptides for maintaining healthy body mass belong -MSH, -MSH and -MSH. Those 
melanocortin vary in their affinity to melanocortin receptors. For example the -MSH has 
highest affinity for  MC4R and -MSH for MC3R (Grieco et al. 2006). 
In POMC neurons the mechanism of intracellular signalling is quite intricate, but it is 
accepted that steps to achieve individual peptides are under multihormonal control. The 
processing includes cleaving the peptide by propeptide convertases PC1 and PC2. Both 
proteinases are able to cleave POMC at distinct pairs of basic residues. It is shown that PC2 has 
much larger spectrum of distribution in brain than PC1 (Benjannet et al. 1991). 
 
 
Figure 4 - Hypothalamic post-translational processing of POMC. PC1 cleaves POMC to pro-ACTH and β-
lipotropin (β-LPH). Pro-ACTH is than cleaved yet again by PC1 to N-terminal peptide (N-POC) and ACTH. PC2 
than cleaves ACTH to α-MSH and corticotropin-like intermediate peptide (CLIP). PC2 also generates Γ-MSH by 
cleaving N-POC. β-LPH is cleaved by PC2 to γ-LPH and β -endorphin (β-END). Β-MSH is cleaved from γ-LPH 
by PC2. Adopted from (Caruso et al. 2012) 
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Insulin receptors are expressed in noticeable population of POMC neurons, through 
those receptors, insulin is able to activate phosphatidylinositol-3 kinase (PI3K) pathway. Both 
leptin and insulin activate distinctive signalling pathways in POMC neurons in ARC (Benoit et 
al. 2002). Melanocortin receptors will be covered in depth in the following chapter. 
POMC deficiencies phenotype is mostly defined by adrenal failure, hyperphagia, early 
onset obesity, changed pigmentation and tall statue. Mendelian POMC is very rare, but it may 
take part in predispositions of obesity. Carriers of heterozygous mutation in POMC have only 
slightly higher or even normal weight.  
One of the first reported POMC deficiency was documented in 1998. Both probands 
were children with seemingly same phenotype. Both subjects developed severe early-onset 
obesity with hyperphagia and pale skin with red hair as a result of flawed MC1R signalling in 
melanocytes in hair follicles. Proband number one had 2 nonsense mutations in exon 3. Proband 
number two was homozygous for mutation in 5´untranslated region that interfered with 
initiation of translation (Coll and Loraine Tung 2009). 
One of the mutations that may also occur is a missense mutation in the cleavage site 
between -MSH and -endorphin. The resulting gene form an aberrant protein, which then 
binds to MC4R, and has a reduced ability to activate said receptor and thus cause obesity 
(Challis et al. 2002). 
World-wide, the prevalence of patients with diagnosed mutation in POMC gene is very 
low, for example complete lack of  POMC (homozygous mutation) was described in only few 
cases. Fortunately for treatment of obesity due to pro-opiomelanocortin deficiency was 













5. Melanocortin receptors 
Melanocortin receptors are members of “A” family rhodopsin-like G-protein coupled receptors 
(GPCR). GPCR are one of vastest class of cell surface proteins and many stimulants like 
peptides, photons or large glycoprotein hormones depend on those receptors to relay 
information by activating G-proteins and effectively increase cAMP production. There are 
5 melanocortin receptors named from MC1R to MC5R, according to their cloning sequence. 
Both MC3R and MC4R are expressed in brain as they are both part of melanocortin pathway. 
MC3R is expressed in hypothalamus and few regions of brainstem, MC4R on the other hand as 
stated in previous chapter, is expressed in brain more intensively in regions such as 
hypothalamus, thalamus, and cortex. MC5R is located in peripheral tissues and has ties to 
exocrine gland functions (Tao and Segaloff  2003). Neither MC1R nor MC2R do not have 
significant ties to the monogenic obesity and will therefore not be discussed in this work. 
 
5.1. Melanocortin-4 receptor 
Melanocortin-4 receptor (MC4R) is one of the most important parts of the whole leptin-
melanocortin pathway. The gene for this receptor is located on chromosome 18q22 has only 
one exon, and the resulting protein is composed of 332 AA. To be fully functional the receptor 
must have His-DPhe-Arg-Trp AA sequence (Holder et al. 2002).  
Many studies have reported numerous mutations connected to the non-syndromic 
obesity. In fact MC4R mutations are the most common cause of monogenic obesity, with 
prevalence of 2,4 % in severely obese Czech children who have early-onset obesity (Hainerová 
et al. 2007). Depending on penetration, the phenotype with exception of obesity, may vary. 
MC4R deficiency includes hyperphagia, food seeking behaviour, linear growth and although, 
hyperinsulinemia is present, distinct lack of diabetes. Remarkable is that children are more 
affected by hyperinsulinemia than equally impaired adults. It also seems like MC4R deficiency 
creates less intensive hyperphagia than deficiency in leptin receptor (Farooqi et al. 2000).In 
comparison to the other monogenic obesity syndromes, pubertal development and reproduction 
is not affected in MC4R deficient patients. MC4R is a prime target for pharmacological research, 




The first MC4R mutation was reported in 1998. And since then 70 mutations were 
described in patients which varied in ethnicity and age. Mutations included deletions, nonsense, 
missense and frameshift mutations dispersed though out the whole receptor.  
It is possible to divide those mutation into 5 classes. 
 
 
Figure 5 - MC4R schematic, Class I mutations – red color,Class II – blue color, Class III – orange, Class IV - green - Class V 












5.1.1. Class I. – Null mutations 
Mutations W16X, Y35X and L64X are suggested to belong there as these mutants do 
not yield receptor protein due to defective synthesis or accelerated degradation. There is 
however little evidence of this. 
5.1.2. Class II. – Intercellularly trapped mutants 
Mutations L106P, I125K, P299H and many more belong to this class and make it the 
biggest class of MC4R mutations. 
5.1.3. Class III. – Binding defective mutants 
Mutations I137T, N97D and I316S show approximately normal expression on the cell 
surface, but binding of ligands is defective due to decreased amount of maximal binding or 
impaired binding affinity. 
5.1.4. Class IV. – Signalling defective mutants 
Mutations I137T, A175T, V253I may belong to this class. These receptor mutations are 
expressed on cell surface and bind ligands with little difficulty, however agonist-stimulated 
signalling is defective. 
5.1.5. Class V. – Variants with unknown defects 
These mutations behave similarly to the wild type in heterogenous system. Some 
express normal cell surface, ligand binding and even agonist-stimulated cAMP. How and if 
those mutations cause obesity is still unclear (Tao and Segaloff  2003). 
Most mutations were found in heterozygous form with notable exception of mutation 
N62S. Patients with this mutation in heterozygous form were not obese (Farooqi et al. 2000).  
During the research of polygenic obesity via Genome wide-association study (GWAS), MC4R 











5.2. Melanocortin – 3 receptor 
Human melanocortin-3 receptor is single exon gene encoding 360 AA protein mapped 
to the 20q13.2 region. It could be assumed that, from its position in brain as well as its structure, 
MC3R may be a strong candidate for possible monogenic cause of obesity; however, this 
receptor has always been controversial in this regard.  
Studies have shown that patients with two missense mutations namely, Thr6Lys and 
Val81Ile in homozygous form, had greater BMI score, leptin and insulin levels and fat tissue 
mass. Double mutants MC3R had also significantly lower ligand binding capacity. In terms of 
difference between races, particularly African-American children were partial for being double-
homozygous for these variants (Feng et al. 2005). 
Another research has uncovered I335S mutation, which has been implied in pathogenic 
mutation, that mutation leaves receptor without any ligand binding or signalling due to 
intracellular retention. It is a known fact, that intracellular retentions are one of the most 
common defects or naturally ensuing mutation (Tao 2007). All this evidence suggests some 
role of MC3R in obesity, but it is still not clear if the mutations in MC3R may be classified as 

















6. BDNF (Brain derived Neurotrophic factor) 
BDNF is a member of neurotrophins, small secretory proteins with significant roles in 
development and protection of nervous system. These proteins are particularly copious in 
central nervous system, most notably in VMH; levels of BDNF grow significantly in post-natal 
development. Studies show that neurotrophins are indispensable for body weight control, for 
example low circulating levels are correlated with type 2 diabetes and obesity. There is evidence 
showing that circulating levels of BDNF are regulated by plasma levels of glucose (Krabbe et 
al. 2007). 
Human BDNF gene can be targeted to locus 11q14.1 containing 11 exons and 9 
functional promoters that are activated tissue and brain-region specifically. BDNF gene 
Encodes 247 AA preprotein which is later cleaved to form fully mature 120 AA protein. This 
protein is fully conserved across the species. BDNF expression is regulated mostly by MC4R 
signalling. 
In Bdnf knock-out mice the phenotype consists of obesity, developed hyperphagia and 
is over all very similar to MC4R deficient mice (Friedel et al. 2005). 
Missense mutation in BDNF receptor TrkB, encoded by NTRK2 gene on 9 chromosome 
is associated with weight gain, obesity and hyperphagia. In obese mouse model with type 2 
diabetes adding BDNF exogenously and transferring BDNF gene leads to weigh loss and 
decreased insulin resistance. This evidence suggests that BDNF brain deficit is indeed cause of 















7. SIM1 (Single-minded 1) 
Protein single minded 1 (SIM1) is transcription factor with basic helix-loop-helix 
conformation. It is expressed in developing nervous system and has crucial role in development 
of several nuclei in hypothalamus, mainly in those which are connected to energy homeostasis 
like paraventricular nuclei (PVN) and supraoptic nuclei (SON) (Michaud et al. 2001, 1). 
Various studies marked SIM1 as a candidate for a cause of human obesity. SIM1-
haploinsuficient mice are hyperphagic, obese and exceptionally sensitive to diet-caused obesity, 
phenotype which closely resembles mice with lack of MC4R. On the other hand, 
overexpression leads to reduction of food intake, however the correlation between MC4R-null 
mice and haploinsuficient-SIM1 is not as straight forward. SIM1 deficiency is associated with 
hyperphagic obesity alongside normal energy expenditure. 
In humans, the deletions in 6q16 chromosome, which houses SIM1 gene, have been 
identified in obese patients with Prader-Willi like (PWL) syndrome characterised by early-onset 
development delay, hypotonia, and later on by obesity, hyperphagia and facial dysmorphism.  
SIM1 non-syndromic mutations were found in many patients with severe obesity, both 
associated and independent of PWL-related phenotype. Some mutations seriously decrease 
SIM1 activity and can be found only in obese people. This suggests that SIM1 mutations may 
indeed be part of monogenic causes of obesity. However not every mutation in this gene is 
responsible for obese phenotype, because it is indicated that environment and genetic 















8. PC1/3 – (Prohormone convertase) 
Prohormone convertase 1/3 (PC1/3) is a major enzyme tied with processing and 
maturation of neuropeptide precursors and prohormones. It is encoded by PCSK1 gene and 
synthetized in endoplasmic reticulum (ER). Between the most important processing substrates 
of PC1/3 belong proopiomelanocortin, proinsulin and proglucagon. 
PC1/3 is synthetized in inactivated form, and in order to activate this precursor, two 
significant events have to occur. Firstly, the N-terminal must be cleaved within ER to yield 85 
kDa precursor, and secondly another cleaving transpires and generates fully active 66 kDa 
PC1/3 isoform (Lloyd, Bohan, and Gekakis 2006). 
It is intriguing that while human with mutated PC1/3 display obese phenotype, knock-
out mice do not display obesity but show multiple growth and endocrinologic problems. This 
leads to assumption that PC1/3 in human and mice serves slightly different purpose. 
Causal unambiguous mutations in PC1/3 are very rare, but for example a missense 
mutation Ser307Leu was found in Libyan child with severe early-onset obesity, whose parents 




















9. Future treatment 
As the threat of obesity is steadily rising, there is certain pressure on pharmaceutical 
companies to provide a magical cure in form of a safe and effective drug. This chapter will be 
dedicated to future possibilities of treatment of monogenic obesity, and perhaps even obesity 
itself.  
For a long time obesitologists did not have any effective and safe drugs to use to treat 
their patients with obesity; not including those few people in the world who have LEP 
deficiency and therefore may be effectively treated with leptin shots. 
MC4R is viewed as one of the promising targets for drug therapy of obesity, currently 
two approaches of affecting functions or emend the damage of MC4R are tested on 
experimental models, some are already in clinical stage.  
First approach concentrates on a search for appropriate molecular and chemical 
chaperones to correct the misfolding of MC4R mutants. This approach is however hindered 
with non-specific effect of chaperones and the necessity of high therapeutic dosage. Out of 
many tested pharmacological chaperones the most promising seem to be Ipsen 5i and Ipsen 17 
(Huang, Wang, and Tao 2017). 
Second approach is centred on search for suitable MC4R agonist or a molecule capable 
of binding receptor and starting signalling cascade resulting in biological response. 
Aforementioned agonist can be sorted into three groups based on their chemical nature. 
1.) Linear peptide agonist 
Various linear peptide analogues of α-MSH with changed AA, are tested for more 
prominent effect than that of natural α-MSH.  
2.) Cyclic peptide agonist 
Majority of cyclic substances tested against MC4R posses short sequence, from four 
to eight AA of core unit from α-MSH (His-Phe-Arg-Trp), which is vital for MC4R 
binding and cyclised by disulphide bonds. For example, setmelanotide belongs to 
this group, containing 8 cyclically bonded AA from natural α-MSH sequence, but 
with four interchanged AA. 
3.) Non-peptide agonist 
Many substances, from the simplest to more complicated organic compounds, were 
tested for their potential to bind to MC4R (Gonçalves, Palmer, Meldal 2018). 
23 
 
One of the potential medications is a “Setmelanotide”, a cyclic peptide binding with 
high affinity to human MC4R mostly in lateral hypothalamic area (LHA). It has proved to lower 
food intake and body weight as well as re-establish insulin sensitivity in mice, dogs and 
monkeys. Due to test on MC4R knockout mice, where it failed to provide any response in terms 
of weight loss, it is possible to suggest that the area of effect is indeed MC4R (Collet et al. 
2017). 
Therapy for Hyperphagia and obesity caused by POMC deficiency is based on agonist 
that substitute lack of MSH binding to MC4R and in result replace the function of POMC in 
leptin-melanocortin pathway. Preliminary studies have shown that such agonist as 
“Setmalnotide” indeed allowed patients to lose considerable amount of body weight (Kühnen 
et al. 2016). 
Leptin receptor defect may also be cured by “Setmelanotide”, since its small molecules 
are expected to be able to directly stimulate nerves that control appetite, bypassing the need for 
leptin., resulting in lower weight and reduced desire for food (Public summary of opinion on 
orphan designation Setmelanotide for the treatment of leptin receptor deficiency b.r.). 
Sermelanotide is also discussed to have effect on PWS, signifficantly increasing resting 
energy expediture (REE) and increasing fat oxidation in obese individuals. Trials have so far 











    
Figure 6 - Chemical structure of Setmelanotide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-
(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-
ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-
carboxamide (IUPAC nomenclature); adopted from (Setmelanotide|RM-493;BIM-22493;IRC-022493|CAS 920014-72-8 Buy 




In the spring of 2019 “Setmelanotide” was approved by European Commission for 
treatment of rare diseases i.e. obesity due to pro-opiomelanocortin deficiency and obesity due 
to leptin receptor gene deficiency (Public Health - European Commission b.r.). 
In the last stage of clinical testing “setmelanotide” is being used to treat obesity caused 
by PWS, BBS, Alström Syndrome and POMC Heterozygous Deficiency Obesity. 
Another potential drug, that should be mentioned, is RM-853, which inhibits ghrelin o-
acyltransferase and is currently in first stages of clinical trials (“OUR PIPELINE.” n.d. Rhythm 
Pharmaceuticals). 
While the hunt for effective drug continues, treatments based on rational diet and, if 
possible, lifestyle change are still considered the most effective non-invasive way of preventing 























Obesity as a whole is still growing problem that may well in future endanger millions 
of people. Diagnosis of obese patients may be divided in to three major categories: Syndromic 
obesity, Polygenic obesity and Monogenic obesity.  
Participation of central nervous system, mainly in monogenic obesity, is non-
questionable, as energy homeostasis and regulation of metabolism fall to this organ. Particularly 
hypothalamus and its neural leptin melanocortin pathway gained much spotlight in this regard.  
The discovery of possible obesity-causing genes has brought hope for those suffering 
from monogenic obesity. Especially afflicted children may now be assessed much easier as the 
options for the diagnosis are growing. 
Most of the genetic mutations share very similar phenotype of increased food intake 
followed by hyperphagia and obesity. Even though many of the most common gene mutations 
are known to this day, many more are still waiting to be discovered.  
One of the most common causes of ebesity is mutation in receptor MC4R, tied with 
melanocortin pathway. On the other hand, it’s still debated whether or not is MC3R cause of 
full scale obesity phenotype. LEP and LEPR have been studied thoroughly for their 
participation in obesity phenotype, mainly through model Ob/Ob and Db/Db mice. Mutation in 
another gene, PC1/3, is entwined with POMC as PC1/3 cleaves POMC into its many 
neuropeptides.  Following this logic mutation in PC1/3 has to, among others, affect POMC 
function. SIM1 is an analogue of Drosophila single-minded gene and is associated with PWL 
syndrome. BDNF plays role in glucose metabolism and has negative impact on obesity and type 
2 diabetes. 
While main genetic animal model is a mouse, it is very important to remember that not 
every mutation found in animals is going to cause the same phenotype in human, e.g. mutation 
in PC1/3 express obese phenotype in human but not in mice, where it causes growth retardation. 
Fortunately for future treatments of obese patients, many new drugs are in process of 
development or are being already clinically tested. It yet remains to be seen if the developed 
drugs for monogenic obesity have the same effect on obesity in general.  New treatment options 
emphasise routine gene mutation diagnosis for patients where monogenic type of obesity is 
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